NDA amendment expected by July with data from 50 additional patients enrolled after the initial filing of the injectable tretinoin NDA for acute promyelocytic leukemia patients who are unable to take the oral form. Aronex had received a "not approvable" letter after the December 1998 NDA submission (1"The Pink Sheet" Oct. 4, 1999, In Brief). At ASCO, Aronex presented Phase II data included in the NDA. In the 75-patient trial, 56 patients were evaluable. Among newly diagnosed APL patients, complete remission rates were 87%, compared with 55% among all relapsed patients. Complete remission rates were 78% for first relapses that were oral Atragen-naive (Group 1) and 23% for second relapses or relapses that had received oral Atragen within one year (Group 2). "One-year survival was 87%, 62.5% and 23% for newly diagnosed, relapse Groups 1 and 2 patients, respectively," a study abstract states
You may also be interested in...
FDA notified the firm that its injectable tretinoin product for acute promyelocytic leukemia is "not approvable." A scheduled review of the drug by FDA's Oncologic Advisory Committee was previously cancelled (1"The Pink Sheet" Aug. 9, In Brief)
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials